Aclimostat

Aclimostat (ZGN-1061) is a potent inhibitor of the MetAP2 enzyme and displays favorable efficacy and safety in preclinical studies. ZGN-1061 produced similar efficacy as beloranib for weight loss, improvements in metabolic parameters in a mouse model of obesity and insulin resistance, and concordant changes in gene transcription in HepG2 cells[1].

Product Specifications

CAS Number

[2082752-83-6]

Product Name Alternative

ZGN-1061

UNSPSC

12352005

Target

MetAP

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/aclimostat.html

Purity

98.0

Solubility

DMSO : 230 mg/mL (ultrasonic)

Smiles

C[C@]1([C@H](O1)C/C=C(C)\C)[C@]2([H])[C@]3(CC[C@H]([C@H]2OC)OC(N4CC(C4)CCN5CCOCC5)=O)CO3

Molecular Formula

C26H42N2O6

Molecular Weight

478.62

References & Citations

[1]Burkey BF, Hoglen NC, Inskeep P, Wyman M, Hughes TE, Vath JE. Preclinical Efficacy and Safety of the Novel Antidiabetic, Antiobesity MetAP2 Inhibitor ZGN-1061. J Pharmacol Exp Ther. 2018 May;365 (2) :301-313.